Summary:
A phase II randomised, double-blind, placebo-controlled study to
evaluate the efficacy, safety, and tolerability of orally administered BI
409306 during a 28-week treatment period as adjunctive therapy to
antipsychotic treatment for the prevention of relapse in patients with
schizophrenia.
Qualified Participants Must:
• Male or female patients
•
ICD-10 diagnosis of schizophrenia older than one year prior to randomisation
Qualified Participants May Receive:
Compensation for time and travel